Conformation-Dependent Anti-Amyloid Oligomer Antibodies

Rakez Kayed, Charles G. Glabe

Research output: Contribution to journalArticle

123 Citations (Scopus)

Abstract

Although abundant evidence suggests that amyloid accumulation plays a significant role in the pathogenesis of degenerative disease, the mechanism of amyloid formation and toxicity remains elusive. Early hypotheses for disease pathogenesis proposed that large amyloid deposits, which are composed primarily of 6-10-nm mature amyloid fibrils, were the primary causative agent in pathogenesis, but this hypothesis required modification to consider the central role of oligomers or aggregation intermediates, because the accumulation of these large aggregates does not correlate well with pathogenesis. Recent evidence supports the hypothesis that small soluble aggregates representing intermediates in the fibril assembly process may represent the primary culprits in a variety of amyloid-related degenerative diseases. Investigating the role of soluble amyloid oligomers in pathogenesis presents a problem for distinguishing these aggregates from the mature fibrils, soluble monomer, and natively folded precursor proteins, especially in vivo and in complex mixtures. Recently, we generated a conformation-specific antibody that recognizes soluble oligomers from many types of amyloid proteins, regardless of sequence. These results indicate that soluble oligomers have a common, generic structure that is distinct from both fibrils and low-molecular-weight soluble monomer/dimer. Conformation-dependent, oligomer-specific antibodies represent powerful tools for understanding the role of oligomers in pathogenesis. The purpose of this chapter is to review the methods for the production, characterization, and application of this antibody to understanding the contribution of amyloid oligomers to the disease process.

Original languageEnglish (US)
Pages (from-to)326-344
Number of pages19
JournalMethods in Enzymology
Volume413
DOIs
StatePublished - 2006
Externally publishedYes

Fingerprint

Oligomers
Amyloid
Conformations
Antibodies
Amyloidogenic Proteins
Monomers
Protein Precursors
Amyloid Plaques
Complex Mixtures
Dimers
Molecular Weight
Toxicity
Deposits
Agglomeration
Molecular weight

ASJC Scopus subject areas

  • Biochemistry

Cite this

Conformation-Dependent Anti-Amyloid Oligomer Antibodies. / Kayed, Rakez; Glabe, Charles G.

In: Methods in Enzymology, Vol. 413, 2006, p. 326-344.

Research output: Contribution to journalArticle

Kayed, Rakez ; Glabe, Charles G. / Conformation-Dependent Anti-Amyloid Oligomer Antibodies. In: Methods in Enzymology. 2006 ; Vol. 413. pp. 326-344.
@article{581659f4232f4df88a7e5616f853422f,
title = "Conformation-Dependent Anti-Amyloid Oligomer Antibodies",
abstract = "Although abundant evidence suggests that amyloid accumulation plays a significant role in the pathogenesis of degenerative disease, the mechanism of amyloid formation and toxicity remains elusive. Early hypotheses for disease pathogenesis proposed that large amyloid deposits, which are composed primarily of 6-10-nm mature amyloid fibrils, were the primary causative agent in pathogenesis, but this hypothesis required modification to consider the central role of oligomers or aggregation intermediates, because the accumulation of these large aggregates does not correlate well with pathogenesis. Recent evidence supports the hypothesis that small soluble aggregates representing intermediates in the fibril assembly process may represent the primary culprits in a variety of amyloid-related degenerative diseases. Investigating the role of soluble amyloid oligomers in pathogenesis presents a problem for distinguishing these aggregates from the mature fibrils, soluble monomer, and natively folded precursor proteins, especially in vivo and in complex mixtures. Recently, we generated a conformation-specific antibody that recognizes soluble oligomers from many types of amyloid proteins, regardless of sequence. These results indicate that soluble oligomers have a common, generic structure that is distinct from both fibrils and low-molecular-weight soluble monomer/dimer. Conformation-dependent, oligomer-specific antibodies represent powerful tools for understanding the role of oligomers in pathogenesis. The purpose of this chapter is to review the methods for the production, characterization, and application of this antibody to understanding the contribution of amyloid oligomers to the disease process.",
author = "Rakez Kayed and Glabe, {Charles G.}",
year = "2006",
doi = "10.1016/S0076-6879(06)13017-7",
language = "English (US)",
volume = "413",
pages = "326--344",
journal = "Methods in Enzymology",
issn = "0076-6879",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Conformation-Dependent Anti-Amyloid Oligomer Antibodies

AU - Kayed, Rakez

AU - Glabe, Charles G.

PY - 2006

Y1 - 2006

N2 - Although abundant evidence suggests that amyloid accumulation plays a significant role in the pathogenesis of degenerative disease, the mechanism of amyloid formation and toxicity remains elusive. Early hypotheses for disease pathogenesis proposed that large amyloid deposits, which are composed primarily of 6-10-nm mature amyloid fibrils, were the primary causative agent in pathogenesis, but this hypothesis required modification to consider the central role of oligomers or aggregation intermediates, because the accumulation of these large aggregates does not correlate well with pathogenesis. Recent evidence supports the hypothesis that small soluble aggregates representing intermediates in the fibril assembly process may represent the primary culprits in a variety of amyloid-related degenerative diseases. Investigating the role of soluble amyloid oligomers in pathogenesis presents a problem for distinguishing these aggregates from the mature fibrils, soluble monomer, and natively folded precursor proteins, especially in vivo and in complex mixtures. Recently, we generated a conformation-specific antibody that recognizes soluble oligomers from many types of amyloid proteins, regardless of sequence. These results indicate that soluble oligomers have a common, generic structure that is distinct from both fibrils and low-molecular-weight soluble monomer/dimer. Conformation-dependent, oligomer-specific antibodies represent powerful tools for understanding the role of oligomers in pathogenesis. The purpose of this chapter is to review the methods for the production, characterization, and application of this antibody to understanding the contribution of amyloid oligomers to the disease process.

AB - Although abundant evidence suggests that amyloid accumulation plays a significant role in the pathogenesis of degenerative disease, the mechanism of amyloid formation and toxicity remains elusive. Early hypotheses for disease pathogenesis proposed that large amyloid deposits, which are composed primarily of 6-10-nm mature amyloid fibrils, were the primary causative agent in pathogenesis, but this hypothesis required modification to consider the central role of oligomers or aggregation intermediates, because the accumulation of these large aggregates does not correlate well with pathogenesis. Recent evidence supports the hypothesis that small soluble aggregates representing intermediates in the fibril assembly process may represent the primary culprits in a variety of amyloid-related degenerative diseases. Investigating the role of soluble amyloid oligomers in pathogenesis presents a problem for distinguishing these aggregates from the mature fibrils, soluble monomer, and natively folded precursor proteins, especially in vivo and in complex mixtures. Recently, we generated a conformation-specific antibody that recognizes soluble oligomers from many types of amyloid proteins, regardless of sequence. These results indicate that soluble oligomers have a common, generic structure that is distinct from both fibrils and low-molecular-weight soluble monomer/dimer. Conformation-dependent, oligomer-specific antibodies represent powerful tools for understanding the role of oligomers in pathogenesis. The purpose of this chapter is to review the methods for the production, characterization, and application of this antibody to understanding the contribution of amyloid oligomers to the disease process.

UR - http://www.scopus.com/inward/record.url?scp=33749507375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749507375&partnerID=8YFLogxK

U2 - 10.1016/S0076-6879(06)13017-7

DO - 10.1016/S0076-6879(06)13017-7

M3 - Article

C2 - 17046404

AN - SCOPUS:33749507375

VL - 413

SP - 326

EP - 344

JO - Methods in Enzymology

JF - Methods in Enzymology

SN - 0076-6879

ER -